Selexis
Chemicals & Related Products · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
55 New Montgomery St Ste 605, San Franci...Phone Number
(508) 485-9262Website
www.selexis.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Selexis
KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO) specializing in biopharmaceutical development and manufacturing services. They offer a comprehensive range of services including cell line development, process development, analytical development, and both clinical and commercial manufacturing for mammalian and microbial systems. Their innovative technologies, such as the SUREtechnology Platform and PUREplatform, enhance the efficiency and quality of therapeutic protein production. KBI Biopharma aims to support clients in the biopharmaceutical industry by providing cutting-edge solutions that positively impact patient lives worldwide.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Selexis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Selexis
Click to see if Selexis had a recent Job posting/layoffs
Selexis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Selexis has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Selexis recently announced quarterly report
Funding: Get notified immidiatlly once Selexis has new funding data
Product Launch: Get notified when Selexis launches new products
Check out if Selexis is spiking on competitors!
Recommended Actions
Find VP level buyers at Selexis
Find 2 more new buyers
Company Profile Activity
Activity Insights
Selexis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Selexis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Selexis.
Selexis Tech Stack
A closer look at the technologies used by Selexis
Most Recent Scoops
Event
will be attending the 15th Annual PEGS Europe 2023 conference as an exhibitor. The event will occur from November 14 to November 16, 2023.
Events
New Hire
Executive Move
Selexis has announced that J.D. Mowery has joined the organization as Chief Executive Officer. Previously, Mowery served as Chief Operating Officer for Treadwell Therapeutics.
Event
will be attending the CPHI Japan 2023 conference as an exhibitor. The event will occur from April 19 to April 21, 2023.
Event
will be attending the 22nd Annual PepTalk 2023 conference as an exhibitor. The event will occur from January 16 to January 20, 2023.
Events
New Hire
Executive Move
Selexis News & Media
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening
GENEVA--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. The swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Selexis, all13 biotech companies to discover in the Swiss Health Valley in 2023 - Labiotech
Here are 13 biotech companies you should know about in 2023 in the Health Valley, the western part of Switzerland!KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer. Toumi brings more than two decades of global expertise in biotech, pharmaceutical, and CDMO industries, demonstrating visionary and strategic leadership. In his role, Toumi will lead Global Business Development for KBI and Selexis, spearheading the long-term client growth strategy and the building of key stratSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform™
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Selexis
Sign Up For FreeTo access detailed company insights
KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO) specializing in biopharmaceutical development and manufacturing services. They offer a comprehensive range of services including cell line development, process development, analytical development, and both clinical and commercial manufacturing for mammalian an... Read More
